Stockwatch: A slimmer AstraZeneca starts to look tasty
This article was originally published in Scrip
Executive Summary
The headline number when AstraZeneca announced its full-year 2011 results on February 2 was not the sales or earnings numbers, but the 7,300 further job losses from R&D, sales and marketing, and manufacturing (scripintelligence.com, 3 February 2012). The AstraZeneca share price finished the day down nearly four percent as investors' concerns with the lacklustre financial results and 2012 outlook were compounded by another restructuring.